396 related articles for article (PubMed ID: 25998936)
1. Assessing the potential of the Woman's Condom for vaginal drug delivery.
Kramzer LF; Cohen J; Schubert J; Dezzutti CS; Moncla BJ; Friend D; Rohan LC
Contraception; 2015 Sep; 92(3):254-60. PubMed ID: 25998936
[TBL] [Abstract][Full Text] [Related]
2. UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application.
Haaland RE; Evans-Strickfaden T; Holder A; Pau CP; McNicholl JM; Chaikummao S; Chonwattana W; Hart CE
Antimicrob Agents Chemother; 2012 Jul; 56(7):3592-6. PubMed ID: 22508307
[TBL] [Abstract][Full Text] [Related]
3. A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781.
Clark MR; Johnson TJ; McCabe RT; Clark JT; Tuitupou A; Elgendy H; Friend DR; Kiser PF
J Pharm Sci; 2012 Feb; 101(2):576-87. PubMed ID: 21976110
[TBL] [Abstract][Full Text] [Related]
4. Development and characterisation of a self-microemulsifying drug delivery systems (SMEDDSs) for the vaginal administration of the antiretroviral UC-781.
McConville C; Friend D
Eur J Pharm Biopharm; 2013 Apr; 83(3):322-9. PubMed ID: 23159711
[TBL] [Abstract][Full Text] [Related]
5. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor.
Schwartz JL; Kovalevsky G; Lai JJ; Ballagh SA; McCormick T; Douville K; Mauck CK; Callahan MM
Sex Transm Dis; 2008 Apr; 35(4):414-9. PubMed ID: 18362865
[TBL] [Abstract][Full Text] [Related]
6. The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781.
Bunge K; Macio I; Meyn L; Noguchi L; Parniak MA; Schwartz JL; Moncla B; Hillier S
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):337-43. PubMed ID: 22495787
[TBL] [Abstract][Full Text] [Related]
7. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men.
Ventuneac A; Carballo-Diéguez A; McGowan I; Dennis R; Adler A; Khanukhova E; Price C; Saunders T; Siboliban C; Anton P
AIDS Behav; 2010 Jun; 14(3):618-28. PubMed ID: 19757017
[TBL] [Abstract][Full Text] [Related]
8. Design of tenofovir-UC781 combination microbicide vaginal gels.
Kiser PF; Mahalingam A; Fabian J; Smith E; Damian FR; Peters JJ; Katz DF; Elgendy H; Clark MR; Friend DR
J Pharm Sci; 2012 May; 101(5):1852-64. PubMed ID: 22359356
[TBL] [Abstract][Full Text] [Related]
9. Short-term acceptability of the PATH Woman's Condom among couples at three sites.
Coffey PS; Kilbourne-Brook M; Austin G; Seamans Y; Cohen J
Contraception; 2006 Jun; 73(6):588-93. PubMed ID: 16730489
[TBL] [Abstract][Full Text] [Related]
10. Initial reactions to the Woman's Condom by potential user groups in Shanghai, China.
Coffey PS; Kilbourne-Brook M; Junqing W; Yufeng Z; Hongxin Z; Bin W; Na L; Rui Z; Yuyan L
J Fam Plann Reprod Health Care; 2013 Apr; 39(2):111-20. PubMed ID: 22906855
[TBL] [Abstract][Full Text] [Related]
11. [Current status of the female condom in Africa].
Deniaud F
Sante; 1997; 7(6):405-15. PubMed ID: 9503499
[TBL] [Abstract][Full Text] [Related]
12. Short-term acceptability of the Woman's Condom and influencing factors among internal migrants in China.
Wu J; Zhang J; Li Y; Yang J; Zhou Y; Li Y; Xu S; Zhao R
BMC Public Health; 2019 Oct; 19(1):1410. PubMed ID: 31664963
[TBL] [Abstract][Full Text] [Related]
13. Estimating the hypothetical dual health impact and cost-effectiveness of the Woman's Condom in selected sub-Saharan African countries.
Mvundura M; Nundy N; Kilbourne-Brook M; Coffey PS
Int J Womens Health; 2015; 7():271-7. PubMed ID: 25784820
[TBL] [Abstract][Full Text] [Related]
14. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.
Patton DL; Sweeney YT; Balkus JE; Rohan LC; Moncla BJ; Parniak MA; Hillier SL
Antimicrob Agents Chemother; 2007 May; 51(5):1608-15. PubMed ID: 17353240
[TBL] [Abstract][Full Text] [Related]
15. Performance of the woman's condom among couples in Shanghai, China.
Zirong H; Junqing W; Coffey PS; Kilbourne-Brook M; Yufeng Z; Wang C; Hongxin Z; Bin W; Yuyan L; Hongbo P
Eur J Contracept Reprod Health Care; 2012 Jun; 17(3):212-8. PubMed ID: 22497293
[TBL] [Abstract][Full Text] [Related]
16. Lack of in vitro-in vivo correlation for a UC781-releasing vaginal ring in macaques.
McConville C; Smith JM; McCoy CF; Srinivasan P; Mitchell J; Holder A; Otten RA; Butera S; Doncel GF; Friend DR; Malcolm RK
Drug Deliv Transl Res; 2015 Feb; 5(1):27-37. PubMed ID: 25787337
[TBL] [Abstract][Full Text] [Related]
17. Performance and safety of the second-generation female condom (FC2) versus the Woman's, the VA worn-of-women, and the Cupid female condoms: a randomised controlled non-inferiority crossover trial.
Beksinska ME; Piaggio G; Smit JA; Wu J; Zhang Y; Pienaar J; Greener R; Zhou Y; Joanis C
Lancet Glob Health; 2013 Sep; 1(3):e146-52. PubMed ID: 25104263
[TBL] [Abstract][Full Text] [Related]
18. Current status of topical antiretroviral chemoprophylaxis.
Van Damme L; Szpir M
Curr Opin HIV AIDS; 2012 Nov; 7(6):520-5. PubMed ID: 22918449
[TBL] [Abstract][Full Text] [Related]
19. Comparative crossover study of the PATH Woman's Condom and the FC Female Condom.
Schwartz JL; Barnhart K; Creinin MD; Poindexter A; Wheeless A; Kilbourne-Brook M; Mauck CK; Weiner DH; Callahan MM
Contraception; 2008 Dec; 78(6):465-73. PubMed ID: 19014792
[TBL] [Abstract][Full Text] [Related]
20. Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission.
Akil A; Parniak MA; Dezzuitti CS; Moncla BJ; Cost MR; Li M; Rohan LC
Drug Deliv Transl Res; 2011 Jun; 1(3):209-222. PubMed ID: 22708075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
